Consequences of moving U.S. pharma manufacturing in-country by gender 2017

This statistic shows the results of a survey conducted in the United States in February 2017, by gender. U.S. adults were given a list of 11 options and asked to select which consequences they would expect if U.S. pharma companies were forced to move their manufacturing from abroad back to the U.S. About 42 percent of female respondents said that they would expect higher drug prices, while 41 percent of male respondents indicated the same.

Opinions on consequences in case U.S. pharma companies would be forced to manufacture in-country as of 2017, by gender

Characteristic	Female	Male
Higher drug prices	42%	41%
Lower drug prices	18%	18%
Better quality of drugs	21%	23%
Better quality control	31%	33%
Fairer labor conditions	20%	19%
More jobs for US citizens	48%	44%
Decrease in manufacturing companies	9%	12%
Smaller range of available drugs	14%	15%
Other	1%	0%
Don't know	14%	13%
None of the above	4%	3%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

February 2017

More information

Region

United States

Survey time period

February 6 to 8, 2017

Number of respondents

1,029 respondents

Age group

18 years and older

Method of interview

Online survey

Supplementary notes

Original question: "A lot of US pharma companies manufacture abroad. Which consequences do you expect in case pharma companies were forced to manufacture in the US?" (multiple pick)

Citation formats